Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
TRAW Traws Pharma Inc.
- Stocks
- Healthcare
- NASDAQ: TRAW
Price (delayed)
$1.72
Market cap
$9.57M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$32.73
Enterprise value
-$6.37M
onconova therapeutics, inc. (nasdaq: ontx) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. using a proprietary chemistry platform, onconova has
Highlights
The equity has surged by 119% since the previous quarter
Traws Pharma's net income has plunged by 91% YoY but it has increased by 37% from the previous quarter
The EPS has plunged by 52% YoY but it has grown by 7% from the previous quarter
The quick ratio has declined by 17% since the previous quarter and by 12% year-on-year
Key stats
What are the main financial stats of TRAW
Market
Valuations
Earnings
Shares outstanding
5.56M
Market cap
$9.57M
Enterprise value
-$6.37M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.45
Price to sales (P/S)
52.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-28.05
Revenue
$227,000
Gross profit
$227,000
Operating income
-$142.37M
Net income
-$34.61M
EBIT
-$34.61M
EBITDA
-$34.6M
Free cash flow
-$30.81M
Per share
Balance sheet
Liquidity
EPS
-$32.73
EPS diluted
-$32.81
Free cash flow per share
-$4.42
Book value per share
$1.18
Revenue per share
$0.03
TBVPS
$2.74
Total assets
$19.06M
Total liabilities
$13.06M
Debt
$0
Equity
$6M
Working capital
$8.46M
Debt to equity
0
Current ratio
1.81
Quick ratio
1.53
Net debt/EBITDA
0.46
Margins
Efficiency
Dividend
EBITDA margin
-15,241.9%
Gross margin
100%
Net margin
-15,245.8%
Operating margin
-62,715.9%
Return on assets
-193.2%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-399.5%
Return on sales
-15,245.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TRAW stock price
How has the Traws Pharma stock price performed over time
Intraday
-8.02%
1 week
27.41%
1 month
21.13%
1 year
-88.43%
YTD
-80.63%
QTD
-25.22%
Financial performance
How have Traws Pharma's revenue and profit performed over time
Revenue
$227,000
Gross profit
$227,000
Operating income
-$142.37M
Net income
-$34.61M
Gross margin
100%
Net margin
-15,245.8%
Traws Pharma's net income has plunged by 91% YoY but it has increased by 37% from the previous quarter
The net margin has plunged by 90% YoY but it has grown by 37% from the previous quarter
Price vs fundamentals
How does TRAW's price correlate with its fundamentals
Growth
What is Traws Pharma's growth rate over time
Valuation
What is Traws Pharma stock price valuation
P/E
N/A
P/B
1.45
P/S
52.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-28.05
The EPS has plunged by 52% YoY but it has grown by 7% from the previous quarter
The equity has surged by 119% since the previous quarter
The stock's price to book (P/B) is 50% less than its 5-year quarterly average of 2.9
The price to sales (P/S) is 73% lower than the 5-year quarterly average of 198.9 but 2.1% higher than the last 4 quarters average of 51.7
Efficiency
How efficient is Traws Pharma business performance
TRAW's return on assets has dropped by 162% year-on-year but it is up by 37% since the previous quarter
The ROS has plunged by 90% YoY but it has grown by 37% from the previous quarter
Dividends
What is TRAW's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TRAW.
Financial health
How did Traws Pharma financials performed over time
TRAW's total assets is 46% greater than its total liabilities
Traws Pharma's total liabilities has plunged by 77% from the previous quarter but it has increased by 7% YoY
TRAW's total assets is down by 24% since the previous quarter but it is up by 4.9% year-on-year
The debt is 100% less than the equity
The equity has surged by 119% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.